Skip to main content
. 2020 Apr 9;10(2):54–64. doi: 10.1016/j.cmrp.2020.04.001

Table 3.

Clinical features of the study patients and according to disease severity. IQR = inter quartile range. Numerals in parenthesis represent percentages or IQR. Table modified from Table 1, illustrated in original article. Guan W et al. N Engl J Med. February 28, 2020. https://doi.org/10.1056/NEJMoa2002032.

Characteristic All patients Non-severe disease Severe disease
Age - median (IQR) years
47 (35–58)
45 (54–57)
52 (40–65)
Distribution
no./total no. (%)
 0–14 yr 9/1011 (0.9) 8/848 (0.9) 1/163 (0.6)
 15–49 yr 557/1011 (55.1) 490/848 (57.8) 67/163 (41.1)
 50–64 yr 292/1011 (28.9) 241/848 (28.4) 51/163 (31.3)
 >65 yr 153/1011 (15.1) 109/848 (12.9) 44/163 (27)
 Females
459/1096 (41.9)
386/923 (41.8)
73/173 (42.2)
Median incubation
period days (IQR)
4 (2–7)
4 (2.8–7.0)
4 (2.0–7.0)
Patients with fever 473/1081 (43.8) 391/910 (43) 82/171 (48)
Symptom No. (%)
Conjunctiva cong. 9 (0.8) 5 (0.5) 4 (2.3)
Nasal congestion 53 (4.8) 47 (5.1) 6 (3.5)
Headache 150 (13.6) 124 (13.4) 26 (15)
Cough 745 (67.8) 623 (67.3) 122 (70.5)
Sore throat 153 (13.9) 130 (14) 23 (13.3)
Sputum product 370 (33.7) 309 (33.4) 61 (31.3)
Fatigue 419 (38.1) 350 (37.8) 69 (39.9)
Hemoptysis 10 (0.9) 6 (0.6) 4 (2.3)
Breathlessness 205 (18.7) 140 (15.1) 65 (37.6)
Nausea/vomiting 55 (5) 43 (4.6) 12 (6.9)
Diarrhea 42 (3.8) 32 (3.5) 10 (5.8)
Myalgias/arthralgia 164 (14.9) 134 (14.5) 30 (17.3)
Chills 126 (11.5) 100 (10.8) 26 (15)
Signs of infection
Throat congestion 19 (1.7) 17 (1.8) 2 (1.2)
Tonsils enlarged 23 (2.1) 17 (1.8) 6 (3.5)
Lymphadenopathy 2 (0.2) 1 (0.1) 1 (0.6)
Rash 2 (0.2) 0 2 (1.2)
Coexisting disorder 261 (23.7) 194 (21) 67 (38.7)